Part, Chapter, Paragraph
1 I, 2. 10. 2| progress towards the target tissue.~ ~For Europe, data on the
2 II, 5. 2. 6| presence of less severe tissue damage. For instance, the
3 II, 5. 6. 3| microarchitectural deterioration of bone tissue, with a consequent increase
4 II, 5. 6. 4| musculoskeletal and connective tissue disorders by diagnosis and
5 II, 5. 6. 4| musculoskeletal and connective tissue disorders by diagnosis and
6 II, 5. 9. 5| hyperresponsiveness and tissue damage leading to long-term
7 II, 5. 11. 1| vascular and connective tissue diseases) have manifestations
8 II, 5. 11. 3| metallic ions in the local tissue and generate several types
9 II, 5. 14. 1| destruction of the supporting tissue of the teeth. One consequence
10 II, 5. 14. 3| disadvantage than disease and tissue damage antecedents. Surveillance
11 II, 6. 3. 6| chains, and that blood or tissue for transplants from potentially
12 II, 9. 3. 1| procedures, including guided tissue regeneration and tooth implantation.
13 II, 9. 3. 1| epithelium, connective tissue, vascular tissue, and muscle –
14 II, 9. 3. 1| connective tissue, vascular tissue, and muscle – are affected
15 II, 9. 4. 3| means vaginal and cervical tissue becomes more fragile, resulting
16 III, 10. 2. 4| RNA~Ribonucleic Acid~TMA~Tissue Micro Arrays~UNESCO~United
17 III, 10. 2. 4| high-throughput technologies such as tissue microarrays (so-called TMAs)
18 III, 10. 2. 4| in a larger population of tissue samples. This will provide
19 III, 10. 2. 4| C (2001): Validation of tissue microarrays for immunohistochemical
20 III, 10. 2. 4| Kallioniemi OP (1998): Tissue microarrays for high-throughput
21 III, 10. 2. 4| Kallioniemi OP, Sauter G (2001): Tissue microarrays for rapid linking
22 III, 10. 2. 5| have persisting effects on tissue structure and function,
23 III, 10. 3. 2| environment or in human tissue even decades after their
24 III, 10. 3. 2| immunodeficiency and different types of tissue malformations. These effects
25 III, 10. 3. 3| chains, and that blood or tissue for transplants from potentially
26 III, 10. 4. 2| marked accumulation in~fatty tissue; neurotoxic,~immunotoxic
27 IV, 11. 5 | 11.5. Tissue, cell and organ transplants~ ~
28 IV, 11. 5. 1| of liver, heart, lung and tissue transplantation.~ ~Figure
29 IV, 11. 5. 4| an organ donor is also a tissue donor. Quality and safety
30 IV, 11. 5. 4| traced and reported on the tissue vigilance system if needed.~
31 IV, 11. 5. 5| European Quality System for Tissue Banking:(Public Health 2003)~
32 IV, 11. 5. 5| and safety in relation to tissue banking activities required
33 IV, 11. 5. 6| relating to human organ and tissue transplantation dated January
34 IV, 11. 5. 6| xenotransplantation~1994Recom - Human tissue banks~1994Recom 40 of the
35 IV, 11. 5. 6| origin~1994Recom 1 on human tissue banks~1992 List of tissue
36 IV, 11. 5. 6| tissue banks~1992 List of tissue typing laboratories in the
37 IV, 11. 5. 6| 1983 Essential aspects of tissue typing~1978 Reso - Harmonisation
38 IV, 13. 7 | heart-valves, cornea, skin, foetal tissue, reproductive cells and
